Skip to content
Telehealth Graded

Search Telehealth Graded

Use arrow keys or Tab to browse. Enter opens a result. Escape closes search.

Enter a name or topic to search.

State guide

Iowa Medicaid and GLP-1s

Published by Telehealth Graded · Updated

The takeaway

Iowa lists Wegovy and Zepbound as preferred, then a footnote says weight loss is not covered, leaving three narrow routes unrelated to weight.

Reading the state documents

Preferred does not mean paid for. Iowa's drug list marks Wegovy and Zepbound preferred, then attaches a footnote saying the weight-loss indication is not covered, and points both rows at a prior-authorization form written for people who do not have diabetes and are not asking for weight loss. The three ways through are a cardiovascular history, a sleep study, or a liver biopsy.

3
documents cited
9
sourced facts
3
primary sources

What changed, and what the document says

  1. Preferred, with a footnote that undoes it

    Not covered

    Wegovy and Zepbound both sit in the preferred column carrying comment code 12. The code's own text is the whole policy.

    “PA Required. Weight loss indication not covered”

    Iowa Department of Health and Human Services, Iowa Medicaid — PDL Effective Date July 1, 2026

  2. The exclusion has a rule number behind it

    Not covered

    Iowa does not leave this to policy language. It cites the administrative code section that makes weight loss an excluded medical use.

    “Iowa Administrative Code 441 – 78.2(4) will be denied.”

    Iowa Department of Health and Human Services, Iowa Medicaid — Updated 7/01/2026

  3. And the diabetes criteria say it again

    Not covered

    The anti-diabetic section repeats the point rather than cross-referencing it, so there is no reading it as an oversight.

    “which is not a covered diagnosis of use”

    Iowa Department of Health and Human Services, Iowa Medicaid — Updated 7/01/2026

  4. You have to be screened for diabetes first

    Conditions apply

    The non-diabetes pathway is genuinely for people without diabetes, and the screening is a documented step rather than an assumption.

    “Patient has been screened for and does not have type 1 or type 2 diabetes mellitus”

    Iowa Department of Health and Human Services, Iowa Medicaid — Updated 7/01/2026

  5. Two maintenance doses, and no others

    Conditions apply

    Iowa approves the two doses studied for cardiovascular risk and refuses the rest, which rules out staying on a lower dose that suits you.

    “Maintenance dosages other than 1.7 mg or 2.4 mg once weekly will not be approved for maintenance treatment”

    Iowa Department of Health and Human Services, Iowa Medicaid — Updated 7/01/2026

  6. Twenty weeks to titrate for sleep apnea

    Conditions apply

    The sleep-apnea route has a clock on the ramp, not only on the destination dose.

    “Initiation and escalation dosages will be permitted up to a maximum of 20 weeks prior to reaching the recommended”

    Iowa Department of Health and Human Services, Iowa Medicaid — Updated 7/01/2026

  7. One incretin at a time

    Conditions apply

    Stacking is refused outright, which matters because the compounded market sells combinations.

    “The requested agent will not be used in combination with other incretin mimetics.”

    Iowa Department of Health and Human Services, Iowa Medicaid — Updated 7/01/2026

  8. A cardiology sign-off on the record

    Conditions apply

    The cardiovascular door is not satisfied by the diagnosis alone; standard treatment has to have been considered first.

    “Patient has been evaluated for cardiovascular standard of care treatment”

    Iowa Department of Health and Human Services, Iowa Medicaid — Updated 7/01/2026

  9. An announced October 2026 change

    Context

    Iowa's August 20, 2026 letter announced changes to incretin criteria with an October 1, 2026 effective date. That announcement does not establish whether those changes were implemented or what criteria apply now; check the current criteria before relying on the earlier documents quoted here.

    “Changes to the Preferred Drug List (PDL) effective October 1, 2026.”

    Iowa Department of Health and Human Services (HHS), Iowa Medicaid — August 20, 2026

Telehealth in Iowa

Some providers pay us a commission when you sign up through our links, at no extra cost to you.

Which of these companies serve Iowa?

Of the 387 companies we grade, 34 publish a list of the states they are licensed in. We checked 251 more and found no such list on any page we read; 102 we have not checked either way.

23 of those lists name Iowa: Gala Health, Care Bare Rx, Vita Bella, TelePeptide, Levity, Wisp, WePeptideRx, Ways2Well, TeleClinic, Tyde Wellness, Willow, ZYP Medical, VevaRx, Trimi, Enhance MD, HumeCare+, Rx.com, Mojoon, Peak Wellness, Sprout Health, Allara Health, Mixx Health & Wellness, and Optimized Health. That is a licensure claim each company makes about itself, not something we checked with a state board.

A published list is a starting point, not a guarantee. If availability decides your choice, ask before you pay and get the answer in writing.

Coverage decides what you pay before cash does. See how state Medicaid programs cover GLP-1s and what a prior-authorization denial turns on.

Sources

Source dates below are the dates printed on the documents.

Nothing on this page is medical advice, and nobody here is a clinician. Coverage rules change; check the linked document before you rely on it.

Browse 50 other state guides